The CBD filmstrips were produced at IntelGenx’s manufacturing facility in Montreal under Canadian GPP conditions and registered as a product for sale with Health Canada as a cannabis product governed by the Cannabis Act and with the Australian Department of Health’s Therapeutic Goods Administration as a medicinal cannabis product governed by the Narcotic Drugs Act.
The innovative, rapid acting sublingual filmstrip CBD product is based on proven pharmaceutical drug delivery technology.
In a statement, Dr. Horst Zerbe, CEO of IntelGenx, said the first shipment of commercial quantities of an oral thin film product based on the company’s VersaFilm technology marks an important milestone for IntelGenx.
“We are looking forward to continuing to build a strong partnership with Heritage Cannabis, which shares our commitment to making innovative and high-quality oral thin film products available to medical cannabis consumers,” he added.
Umar Syed, president of medical division at Heritage Cannabis, said the company believes the “future of the oral cannabinoid market will be dominated by products based on innovative technologies such as VersaFilm that can deliver superior absorption and product performance.”